Study guide
15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
Key Takeaways Explain This Topic AI
Myasthenia gravis patients are resistant to suxamethonium (may need about 1.5-2 mg/kg) but very sensitive to non-depolarising blockers, so small titrated doses with quantitative monitoring and sugammadex reversal are preferred.
Lambert-Eaton myasthenic syndrome is caused by antibodies against presynaptic voltage-gated calcium channels, is often associated with small-cell lung cancer, and causes sensitivity to both depolarising and non-depolarising blockers.
Suxamethonium is contraindicated in Duchenne and Becker muscular dystrophy because it can cause hyperkalaemic cardiac arrest and rhabdomyolysis; volatile agents can also trigger rhabdomyolysis.
In myotonic dystrophy, suxamethonium, neostigmine, cold and shivering can provoke myotonic contractures that are not relieved by neuromuscular blockers, and patients are sensitive to sedatives and opioids.
After spinal cord injury, suxamethonium is safe in the first 24-48 hours but should be avoided from about 72 hours to at least 6-12 months because of extrajunctional receptor proliferation and hyperkalaemia.
Last updated: October 2026
- 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
- Principles
Neuromuscular diseases may affect the motor neurone, peripheral nerve, neuromuscular junction or muscle. The site determines the response to drugs:
Site Example Suxamethonium Non-depolarising blockers
Upper motor neurone / denervation Spinal cord injury, stroke, multiple sclerosis, prolonged immobility Hyperkalaemia risk (after about 72 hours) Resistance in the affected limbs
- Postsynaptic junction Myasthenia gravis Resistance Marked sensitivity
- Presynaptic junction Lambert-Eaton syndrome Sensitivity Marked sensitivity
Muscle Muscular dystrophies, myotonic dystrophy Contraindicated (hyperkalaemia, rhabdomyolysis, myotonia) Normal or increased sensitivity
Myasthenia Gravis
An autoimmune disease with antibodies against postsynaptic nicotinic acetylcholine receptors (about 85%) or muscle-specific kinase (MuSK). It causes fatigable weakness of ocular, bulbar, limb and respiratory muscles. Thymoma is present in about 10-15%, and thymic hyperplasia is common.
Treatment: pyridostigmine (anticholinesterase), immunosuppression (prednisolone, azathioprine), intravenous immunoglobulin or plasma exchange before surgery in poorly controlled patients, and thymectomy.
Anaesthetic management:
Assess bulbar function and respiratory reserve (vital capacity); optimise before elective surgery.
Continue pyridostigmine (it may slightly prolong suxamethonium and reduce response to neostigmine).
Suxamethonium: relative resistance because fewer receptors are available; about 1.5-2 mg/kg may be needed.
Non-depolarising blockers: greatly increased sensitivity; avoid if possible, or use about 10-20% of the normal dose with quantitative monitoring . Sugammadex is preferred for reversing rocuronium because neostigmine is unreliable.
Volatile agents and magnesium potentiate weakness; aminoglycosides, some antiarrhythmics and fluoroquinolones can worsen the disease.
Postoperative ventilation is more likely with long disease duration, high pyridostigmine doses, bulbar involvement and low vital capacity.
Myasthenic versus Cholinergic Crisis
- Feature Myasthenic crisis Cholinergic crisis
- Cause Disease exacerbation, infection, under-treatment Excess anticholinesterase
Signs Weakness, respiratory failure Weakness plus muscarinic effects: salivation, sweating, bradycardia, miosis, diarrhoea
Treatment Ventilatory support, plasma exchange or immunoglobulin Stop anticholinesterase, atropine, ventilatory support
Lambert-Eaton Myasthenic Syndrome
Antibodies against presynaptic voltage-gated calcium channels reduce acetylcholine release. About half of cases are paraneoplastic, usually with small-cell lung cancer . Weakness affects proximal limbs, often improves with repeated effort, and is accompanied by autonomic dysfunction (dry mouth, postural hypotension). Patients are sensitive to both depolarising and non-depolarising blockers . Treatment includes amifampridine (3,4-diaminopyridine), which prolongs presynaptic depolarisation.
Muscular Dystrophies
Duchenne muscular dystrophy (X-linked, absent dystrophin) causes progressive weakness from early childhood, cardiomyopathy and respiratory failure. Becker dystrophy is milder.
Suxamethonium is contraindicated: it can cause acute rhabdomyolysis and hyperkalaemic cardiac arrest.
Volatile agents can cause rhabdomyolysis and hyperkalaemia (anaesthesia-induced rhabdomyolysis), so total intravenous anaesthesia is generally preferred. This is distinct from malignant hyperthermia.
Assess cardiac function (echocardiography) and respiratory function; risk of postoperative respiratory failure and aspiration.
Myotonic Dystrophy
An autosomal dominant multisystem disorder (CTG repeat expansion) with myotonia (delayed relaxation), weakness, cardiac conduction defects, cardiomyopathy, cataracts, diabetes, frontal balding and central sleep apnoea.
Triggers of myotonia: suxamethonium, neostigmine, cold, shivering, surgical manipulation and diathermy. The resulting contracture is not relieved by non-depolarising blockers or regional anaesthesia because it originates in the muscle membrane; local anaesthetic infiltration into the muscle, phenytoin or quinine may help.
Sensitivity to sedatives, opioids and anaesthetic agents, with a high risk of postoperative respiratory failure and aspiration.
Short-acting non-depolarising blockers with sugammadex reversal are preferred; avoid neostigmine.
Monitor for arrhythmias and conduction block; pacing may be needed.
Multiple Sclerosis
A demyelinating disease of the central nervous system with relapses and progression.
Relapses may follow surgery, infection, stress and hyperthermia (even small rises in temperature worsen conduction in demyelinated nerves).
General anaesthesia is not known to cause relapse. Epidural anaesthesia with low concentrations is considered acceptable; spinal anaesthesia has been associated with relapse in older reports, but evidence is weak, and the decision should be discussed with the patient.
Avoid suxamethonium in patients with significant weakness or immobility (hyperkalaemia).
Autonomic dysfunction can cause cardiovascular instability.
Parkinson's Disease
Loss of dopaminergic neurones in the substantia nigra causes bradykinesia, rigidity, tremor and autonomic dysfunction.
Continue antiparkinsonian drugs without interruption; give levodopa by nasogastric tube or use a rotigotine patch if the patient cannot swallow. Omission can cause severe rigidity, dysphagia, aspiration and a neuroleptic malignant-like syndrome.
Avoid dopamine antagonists: metoclopramide, prochlorperazine, droperidol and haloperidol.
Risks: aspiration (bulbar dysfunction), postural hypotension, postoperative confusion, and hypotension with propofol in patients with autonomic failure.
MAO-B inhibitors (selegiline, rasagiline) interact with pethidine.
Epilepsy
Continue antiepileptic drugs; give intravenous alternatives (levetiracetam, sodium valproate, phenytoin, lacosamide) when oral intake is interrupted.
Pro-convulsant drugs to avoid or use with care: high-dose enflurane (historical), pethidine (norpethidine), large doses of local anaesthetics, tramadol and hypocapnia. Sevoflurane at high concentrations can produce epileptiform EEG activity.
Enzyme-inducing drugs increase requirements for opioids and non-depolarising blockers.
Spinal Cord Injury
Acute phase: spinal shock with flaccid paralysis and, in high cervical and upper thoracic injuries, neurogenic shock (hypotension and bradycardia from loss of sympathetic outflow above T6). Injuries at C3-C5 affect the diaphragm.
Suxamethonium: safe in the first 24-48 hours; avoid from about 72 hours until at least 6-12 months (some advise longer) because extrajunctional acetylcholine receptors cause dangerous hyperkalaemia.
Autonomic dysreflexia: in chronic lesions above about T6 , stimulation below the lesion (bladder distension, surgery) causes massive sympathetic discharge with severe hypertension and reflex bradycardia. Prevent it with adequate general or neuraxial anaesthesia even when the patient cannot feel the surgery; treat with deepening anaesthesia and vasodilators.
Guillain-Barré Syndrome
An acute inflammatory demyelinating polyneuropathy, often after infection, causing ascending weakness, areflexia and autonomic instability.
Monitor vital capacity : below about 20 mL/kg (or a fall of 30%), inability to cough or bulbar weakness indicates the need for ventilation.
Treatment: intravenous immunoglobulin or plasma exchange; corticosteroids are not effective.
Avoid suxamethonium (hyperkalaemia); autonomic instability causes exaggerated responses to vasoactive drugs and to induction.